OKYO Pharma Advances Urcosimod Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 7 hours ago
0mins
Source: Newsfilter
- Positive FDA Feedback: OKYO Pharma received encouraging feedback during its FDA Type D meeting, validating the clinical development path for Urcosimod, marking a significant milestone in the treatment of neuropathic corneal pain (NCP) and reducing development risks.
- Global Trial Launch: The company plans to initiate the NEPTUNE global trial in the U.S. and Europe, aiming to enroll approximately 111 subjects with a 2:1 randomization of 0.05% Urcosimod versus placebo, addressing a significant unmet medical need.
- Accelerated Development Plan: OKYO intends to seek FDA Breakthrough Therapy Designation (BTD), which may further expedite the development and review process for Urcosimod, enhancing the company's position in the competitive biopharmaceutical market.
- Innovative Treatment Potential: As the first investigational therapy for NCP, Urcosimod has received Fast Track designation from the FDA, indicating its potential to provide new treatment options for patients suffering from this debilitating condition.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OKYO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OKYO
Wall Street analysts forecast OKYO stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.750
Low
5.00
Averages
6.00
High
7.00
Current: 1.750
Low
5.00
Averages
6.00
High
7.00
About OKYO
OKYO Pharma Limited is a United Kingdom-based clinical-stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. It has completed a Phase II trial in patients with DED and NCP. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
OKYO Pharma Advances Urcosimod Clinical Trial
- Positive FDA Feedback: OKYO Pharma received encouraging feedback during its FDA Type D meeting, validating the clinical development path for Urcosimod, marking a significant milestone in the treatment of neuropathic corneal pain (NCP) and reducing development risks.
- Global Trial Launch: The company plans to initiate the NEPTUNE global trial in the U.S. and Europe, aiming to enroll approximately 111 subjects with a 2:1 randomization of 0.05% Urcosimod versus placebo, addressing a significant unmet medical need.
- Accelerated Development Plan: OKYO intends to seek FDA Breakthrough Therapy Designation (BTD), which may further expedite the development and review process for Urcosimod, enhancing the company's position in the competitive biopharmaceutical market.
- Innovative Treatment Potential: As the first investigational therapy for NCP, Urcosimod has received Fast Track designation from the FDA, indicating its potential to provide new treatment options for patients suffering from this debilitating condition.
See More
OKYO Pharma Expands Scientific Advisory Board with New Appointment
- Advisory Board Expansion: OKYO Pharma has appointed Dr. Marta Sacchetti, an associate professor of ophthalmology at Link University in Rome, to its Scientific Advisory Board, aiming to advance its clinical programs in neuropathic corneal pain and inflammatory eye diseases while enhancing its global scientific network.
- Rich Expertise: Dr. Sacchetti brings extensive clinical, research, and industry experience in corneal and ocular surface diseases, having previously served as Global Head of Clinical Development at Dompé Farmaceutici, contributing significant insights into degenerative, allergic, and neuroimmune diseases.
- Enhanced R&D Support: Her expertise in targeted nerve regeneration, pain signaling modulation, and advanced diagnostics will bolster OKYO's development efforts in neuro-inflammatory eye diseases, aiding in the formulation of a robust global clinical development strategy.
- Increased Industry Visibility: OKYO's visibility within the ophthalmology community has improved, particularly through its introduction at the American Society of Cataract and Refractive Surgery meeting, which has driven engagement at both Eyecelerator and the Association for Research in Vision and Ophthalmology conference, thereby enhancing its industry influence.
See More
OKYO Pharma to Present Urcosimod Data at ARVO 2026
- Clinical Trial Results: OKYO Pharma's urcosimod demonstrated significant pain reduction in a Phase 2a clinical trial for neuropathic corneal pain, with clinically meaningful decreases in Visual Analogue Scale (VAS) scores, enhancing patients' quality of life and indicating its potential in treating this condition with no FDA-approved therapies.
- Conference Presentation Opportunity: Chief Scientific Officer Raj Patil, Ph.D., will present these findings at the ARVO 2026 Annual Meeting, highlighting the significance of urcosimod's first-in-human study results in the field of ophthalmology research.
- Future Research Plans: OKYO plans to initiate a multicenter Phase 2b/3 trial involving approximately 150 patients in the coming months to further evaluate urcosimod's efficacy and safety, laying the groundwork for the company's expansion in the ophthalmic drug market.
- FDA Fast Track Designation: Urcosimod has received FDA Fast Track designation, becoming the first IND application for neuropathic corneal pain, showcasing its innovative potential in addressing this serious condition and likely attracting increased investor interest.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Overview of Updates: While specific upgrades and downgrades are not detailed, the overall rating changes may prompt investors to reassess their holdings, potentially affecting trading volumes and price fluctuations of the related stocks.
- Expected Market Reaction: Analyst rating adjustments typically trigger immediate market responses, and investors should monitor these changes to timely adjust their investment strategies and capitalize on potential market opportunities.
- Information Access: Investors can access a comprehensive view of rating changes through Benzinga's analyst ratings page, aiding them in making more informed investment decisions.
See More
OKYO Pharma Prices Public Offering at $1.85 per Share
- Public Offering Pricing: OKYO Pharma Ltd has announced a public offering of 10.82 million shares priced at $1.85 each, with gross proceeds expected to be around $20 million, indicating the company's proactive approach to financing ahead of the offering's expected closure on February 17, 2026.
- Underwriter Selection: Piper Sandler & Co. has been appointed as the sole manager for the offering, reflecting the company's careful and professional selection of partners to ensure a smooth fundraising process.
- Stock Price Fluctuation: Following the announcement, OKYO's stock fell 7.83% in the after-hours market to $2.00, indicating a negative market reaction to the offering, which may impact investor confidence.
- Clinical Development Plans: The company intends to use the net proceeds primarily for clinical development of its product candidates and general corporate purposes, particularly focusing on treatments for neuropathic corneal pain, highlighting its commitment to R&D and potential for future growth.
See More
OKYO Pharma Announces Public Offering of Shares
- Offering Size: OKYO Pharma plans to publicly offer 10,815,000 ordinary shares priced at $1.85 each, aiming to raise approximately $20 million, which could increase to about $23 million if the underwriter exercises its additional purchase option.
- Use of Proceeds: The funds raised will primarily support clinical development, general corporate purposes, and working capital, aimed at bolstering the company's future R&D and operational needs, thereby enhancing its market competitiveness.
- Underwriter Option: The underwriter has a 30-day option to purchase an additional 1,622,250 shares at the public offering price, indicating potential demand for the stock and investor confidence.
- Closing Timeline: The offering is expected to close on or around February 17, 2026, pending customary closing conditions, reflecting the company's positive outlook on future growth.
See More
OKYO Pharma Advances Urcosimod Clinical Trial
- Positive FDA Feedback: OKYO Pharma received encouraging feedback during its FDA Type D meeting, validating the clinical development path for Urcosimod, marking a significant milestone in the treatment of neuropathic corneal pain (NCP) and reducing development risks.
- Global Trial Launch: The company plans to initiate the NEPTUNE global trial in the U.S. and Europe, aiming to enroll approximately 111 subjects with a 2:1 randomization of 0.05% Urcosimod versus placebo, addressing a significant unmet medical need.
- Accelerated Development Plan: OKYO intends to seek FDA Breakthrough Therapy Designation (BTD), which may further expedite the development and review process for Urcosimod, enhancing the company's position in the competitive biopharmaceutical market.
- Innovative Treatment Potential: As the first investigational therapy for NCP, Urcosimod has received Fast Track designation from the FDA, indicating its potential to provide new treatment options for patients suffering from this debilitating condition.
See More
OKYO Pharma Expands Scientific Advisory Board with New Appointment
- Advisory Board Expansion: OKYO Pharma has appointed Dr. Marta Sacchetti, an associate professor of ophthalmology at Link University in Rome, to its Scientific Advisory Board, aiming to advance its clinical programs in neuropathic corneal pain and inflammatory eye diseases while enhancing its global scientific network.
- Rich Expertise: Dr. Sacchetti brings extensive clinical, research, and industry experience in corneal and ocular surface diseases, having previously served as Global Head of Clinical Development at Dompé Farmaceutici, contributing significant insights into degenerative, allergic, and neuroimmune diseases.
- Enhanced R&D Support: Her expertise in targeted nerve regeneration, pain signaling modulation, and advanced diagnostics will bolster OKYO's development efforts in neuro-inflammatory eye diseases, aiding in the formulation of a robust global clinical development strategy.
- Increased Industry Visibility: OKYO's visibility within the ophthalmology community has improved, particularly through its introduction at the American Society of Cataract and Refractive Surgery meeting, which has driven engagement at both Eyecelerator and the Association for Research in Vision and Ophthalmology conference, thereby enhancing its industry influence.
See More
OKYO Pharma to Present Urcosimod Data at ARVO 2026
- Clinical Trial Results: OKYO Pharma's urcosimod demonstrated significant pain reduction in a Phase 2a clinical trial for neuropathic corneal pain, with clinically meaningful decreases in Visual Analogue Scale (VAS) scores, enhancing patients' quality of life and indicating its potential in treating this condition with no FDA-approved therapies.
- Conference Presentation Opportunity: Chief Scientific Officer Raj Patil, Ph.D., will present these findings at the ARVO 2026 Annual Meeting, highlighting the significance of urcosimod's first-in-human study results in the field of ophthalmology research.
- Future Research Plans: OKYO plans to initiate a multicenter Phase 2b/3 trial involving approximately 150 patients in the coming months to further evaluate urcosimod's efficacy and safety, laying the groundwork for the company's expansion in the ophthalmic drug market.
- FDA Fast Track Designation: Urcosimod has received FDA Fast Track designation, becoming the first IND application for neuropathic corneal pain, showcasing its innovative potential in addressing this serious condition and likely attracting increased investor interest.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Overview of Updates: While specific upgrades and downgrades are not detailed, the overall rating changes may prompt investors to reassess their holdings, potentially affecting trading volumes and price fluctuations of the related stocks.
- Expected Market Reaction: Analyst rating adjustments typically trigger immediate market responses, and investors should monitor these changes to timely adjust their investment strategies and capitalize on potential market opportunities.
- Information Access: Investors can access a comprehensive view of rating changes through Benzinga's analyst ratings page, aiding them in making more informed investment decisions.
See More
OKYO Pharma Prices Public Offering at $1.85 per Share
- Public Offering Pricing: OKYO Pharma Ltd has announced a public offering of 10.82 million shares priced at $1.85 each, with gross proceeds expected to be around $20 million, indicating the company's proactive approach to financing ahead of the offering's expected closure on February 17, 2026.
- Underwriter Selection: Piper Sandler & Co. has been appointed as the sole manager for the offering, reflecting the company's careful and professional selection of partners to ensure a smooth fundraising process.
- Stock Price Fluctuation: Following the announcement, OKYO's stock fell 7.83% in the after-hours market to $2.00, indicating a negative market reaction to the offering, which may impact investor confidence.
- Clinical Development Plans: The company intends to use the net proceeds primarily for clinical development of its product candidates and general corporate purposes, particularly focusing on treatments for neuropathic corneal pain, highlighting its commitment to R&D and potential for future growth.
See More
OKYO Pharma Announces Public Offering of Shares
- Offering Size: OKYO Pharma plans to publicly offer 10,815,000 ordinary shares priced at $1.85 each, aiming to raise approximately $20 million, which could increase to about $23 million if the underwriter exercises its additional purchase option.
- Use of Proceeds: The funds raised will primarily support clinical development, general corporate purposes, and working capital, aimed at bolstering the company's future R&D and operational needs, thereby enhancing its market competitiveness.
- Underwriter Option: The underwriter has a 30-day option to purchase an additional 1,622,250 shares at the public offering price, indicating potential demand for the stock and investor confidence.
- Closing Timeline: The offering is expected to close on or around February 17, 2026, pending customary closing conditions, reflecting the company's positive outlook on future growth.
See More
